SEC Form 4 · accession 0001395064-26-000248
TAKEDA PHARMACEUTICAL CO LTD · TAK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lauren Rusckowski Duprey
Officer — Chief Transformation Officer
Period of report
Jul 1, 2026
Accepted (ET)
Jul 6, 2026 · 6:03 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001395064
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| American Depositary SharesF1 | Jul 1, 2026 | A | 45,140 | $0.00 | A | 273,643 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest in three equal annual installments beginning on July 1, 2027.